Year-end Sale % OFF 
Abstract
Hormone receptor status assessment is necessary for selecting cancer patients who might potentially benefit from endocrine therapy. To determine whether hormone receptor status changes during tumor progression, we retrospectively examined 107 high-grade serous ovarian cancer (HGSC) patients with paired primary and recurrent tumor specimens. Hormone receptor expression discordance rates between primary and recurrent tumors were as follows: estrogen receptor (ER) 34.9%, progesterone receptor (PR) 12.4%, androgen receptor (AR) 41.7%, follicle stimulating hormone receptor 46.6%, luteinizing hormone receptor 50.5%, and gonadotropin releasing hormone receptor 20.0%. Hormone receptor discordance was not associated with patient survival. The proportion of the PR-ER+AR- subgroup, which exhibited the worst prognosis, was higher in recurrent than primary tumor specimens. Our study demonstrated that paired primary and recurrent HGSC specimens exhibit differing hormone receptor profiles. Thus, to most effectively identify patient-specific therapies, biomarker status re-assessment is required for recurrent patients.
Highlights
Ovarian cancer is one of the most common and lethal cancers affecting women globally [1]
Hormone receptor status assessment is necessary for selecting cancer patients who might potentially benefit from endocrine therapy
To determine whether hormone receptor status changes during tumor progression, we retrospectively examined 107 high-grade serous ovarian cancer (HGSC) patients with paired primary and recurrent tumor specimens
Summary
Ovarian cancer is one of the most common and lethal cancers affecting women globally [1]. After primary debulking or staging surgery, and subsequent platinumbased chemotherapy, most patients relapse within a median of 16 months [2]. Patients with recurrent ovarian cancer are usually offered several consecutive therapies with variable response rates and prognoses [2]. Hormone therapy is considered a salvage therapy for recurrent disease, and endocrine therapy tends to be more efficacious in hormone receptor positive subgroups [3,4,5,6]. Hormone receptor status assessment is necessary for selecting patients who would potentially benefit from endocrine therapy. Hormone receptors or HER2 status can change during breast cancer progression [7,8,9], whether hormone receptor expression differs between primary and recurrent ovarian cancers is currently unknown
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
